Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Start Date
2/21/2026
Completion Date
1/1/2027
Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. The supplements have been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Detailed Description
This randomized, double-blind, placebo-controlled, two-arm crossover trial will compare the effects of two NAD⁺-modulating interventions-nicotinamide mononucleotide (NMN) with trimethylglycine (TMG) and conventional NMN supplementation-on exercise tolerance and metabolic biomarkers in healthy older adults. The NMN and TMG arm will involve a twice-daily oral dose containing 1000 mg of NMN and 500 mg of TMG, while the comparison arm will involve twice-daily oral dose of 1000 mg of NMN per day. Doses will be self-administered each morning and evening with water. The primary endpoint is time to fatigue during constant work rate cycle ergometry (CWR-Tlim), a validated surrogate for submaximal exercise tolerance. Secondary endpoints include peak oxygen uptake (VO₂peak), lactate threshold, anaerobic work capacity, and critical power, in addition to circulating NAD⁺ and its related metabolites. The trial is designed to evaluate the short-term physiological effects and biological activity of NMN with TMG compared to NMN alone under tightly controlled exercise testing and training conditions. Data from this study will be used to inform the therapeutic potential of an over-the-counter product (Euexia®) in improving physical performance in healthy older adults (60-80 years). Future directions may include further clinical evaluation or regulatory submissions, depending on outcomes from this pilot investigation.
Eligibility Criteria
Age Range: 60 years to 80 years
Interventions
NMN and TMG (Euexia)
Nicotinamide Mononucleotide (NMN)
Placebo
Conditions
Locations
Medical Office of Dr. Robert Huizenga MD
Beverly Hills, California 90210
United States